ISRG — ISRG

Quote unavailable this cycle.

Investment Read as of 2026-06-05

The Read

ISRG is a SOLID investment. Its established, profitable model provides a necessary reality check against the hype cycle of emerging robotics. The running conviction of P=0.65 remains appropriate given the current signals.

Bull case

• Proven Economics: ISRG runs the only scaled, profitable robotics model, relying on high-margin, recurring "razor-and-blades" revenue from its installed base [Thesis].
• Procedure Growth: Continued procedure growth (13.5–15.5%) combined with the large installed base supports predictable revenue streams [Thesis].
• Platform Upgrade Cycle: The da Vinci 5 upgrade cycle provides a clear, near-term revenue driver for placements [Thesis].

Bear case / what breaks it

• Procedure Slowdown: Procedure growth falling below 10% signals a worsening drag, possibly from areas like GLP-1 bariatric procedures [Thesis].
• China Exposure: A collapse in China reimbursement or placements would significantly impact revenue [Thesis].
• Competitive Threat: The emergence of a credible, scaled surgical-robotics competitor poses an existential risk [Thesis].

What the latest signal says

The recent signals focus heavily on academic and early-stage humanoid development (e.g., ladder climbing, gaze learning) [Reddit, arXiv]. These signals reinforce ISRG's role as the *benchmark* for mature robotics economics, contrasting sharply with the unproven, academic nature of the current hype.

Posterior history

Thesis detail

Core thesis

The only proven, scaled, profitable robotics business on earth — da Vinci, 11,395

systems installed, 86% recurring "razor-and-blades" revenue. It's both a quality

holding and the benchmark for what mature robotics economics look like — the

yardstick against which every humanoid hopeful (Optimus, Figure) should be judged.

Pillars (with priors)

1. Only proven scaled, profitable robotics model (recurring razor/blade) · P = 0.85

2. Procedure growth (13.5–15.5%) + installed-base recurring revenue · P = 0.70

3. da Vinci 5 upgrade cycle drives placements · P = 0.65

Expected news (the prior)

• Procedure-growth guidance; da Vinci 5 placements; China reimbursement; recurring-rev mix

Residual = a procedure-growth slowdown, a China collapse, or a credible scaled rival.

Thesis-breaking triggers (→ set P near 0)

• ☐ Procedure growth falls below ~10% (GLP-1 bariatric drag worsens)
• ☐ China reimbursement / placements collapse
• ☐ Tariffs materially hit hardware economics
• ☐ A credible scaled surgical-robotics competitor emerges

Leading vs lagging indicators

• Leading: procedure-growth guide, da Vinci 5 placement mix, China reimbursement policy
• Lagging: revenue, EPS, share price

Key metrics

• Procedure growth % · installed base (11,395) · recurring-rev % (86%) · da Vinci 5 mix

Valuation anchor

Premium quality; proven compounder. Doubles as the **robotics-thesis reality

anchor**: use its economics to pressure-test the humanoid hype in B4.

Cross-arena sensors

B4 (robotics adoption + the demo-vs-real benchmark), B5 (med-tech), B7 (China/tariffs).

Posterior log

• 2026-06-05 · P 0.62→0.65 ↑ · MAINTENANCE · Strengthening — the one hard signal in the window (Unitree's pre-IPO profit plunge) actually *validates* Pillar 1 rather than threatening it
• 2026-05-29 · P 0.47→0.62 ↑ · MAINTENANCE · Strengthening — and the running P of 0.47 is mispriced. Both downgrades were driven by Unitree's pre-IPO profit collapse, but Unitree is a h
• 2026-05-26 · P 0.73→0.60 ↓ · DOWN · · https://www.scmp.com/tech/tech-trends/article/3354855/unitree-robotics-reports-plunge-first-quarter-profits-days-crucial-ipo-hearing?utm_source=rss_feed
• {{date}} · created · — · AI-Energy-Thesis-Scaffold / Own-the-Bottleneck